J&J Deal Lifts Overhang on Elan Stock; Investors Cautious

Sheridan, Cormac
July 2009
BioWorld International;7/8/2009, Vol. 14 Issue 27, p1
The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple sclerosis (MS) patients receiving its anti-alpha4-integrin antibody Tysabri or natalizumab under a partnership with Biogen Idec Inc. Also, mixed results from a trial of the anti-beta-amyloid antibody bapineuzumab in Alzheimer's disease have led to safety concerns.


Related Articles

  • AD Attracts Huge Interest Despite Failures. Powers, Marie // BioWorld Today;8/27/2012, Vol. 23 Issue 166, p5 

    The article reports on the interest of several companies in developing drugs that could cure Alzheimer's disease despite failures in clinical trials, such as Johnson & Johnson, Pfizer Inc. and Elan Corp. PLC's bapineuzumab. Satori Pharmaceuticals is developing a class of oral gamma-secretase...

  • J&J-Pfizer's Alzheimer's Drug Crashes, Burns in Phase III. Sheridan, Cormac // BioWorld International;8/8/2012, Vol. 17 Issue 32, p1 

    The article reports on the failure of Pfizer Inc. and Johnson and Johnson's bapineuzumab to pass the Phase III trial in Alzheimer's disease. It notes that the antibody, which is discovered and developed by Elan Corp. PLC, has failed to meet the co-primary cognitive and functional performance...

  • Elan/Wyeth unveil significant findings from phase IIa trial of AN-1792.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p7 

    Reports on the findings of Elan Corp. and Wyeth Pharmaceuticals Inc.'s phase IIa clinical trial of an investigational Alzheimer's disease treatment drug, AN-1792. Beta amyloid immunotherapy approach; Use of an immunologic approach to clear beta amyloid from the brain; Evidence of beta amyloid...

  • J&J acquires $1B stake in Elan; Interleukin sells unit to Pep.  // Medical Device Daily;7/6/2009, Vol. 13 Issue 127, p5 

    The article reports on the acquisition of Johnson & Johnson (J&J) of the assets and rights of Elan involved in its Alzheimer's Immunotherapy Program (AIP). It furthers that J&J will spend $1 billion in exchange for newly issued American depositary receipts (ADRs) of Elan, forming 18.4% of Elan's...

  • Call for Elan to publish Alzheimer's trial details. Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S. // Nature;4/18/2002, Vol. 416 Issue 6882, p677 

    Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the...

  • Elan's AD Drug Down, Not Out: J&J Pledges $1.5B in Venture. Hollingsworth, Catherine // BioWorld International;7/8/2009, Vol. 14 Issue 27, p3 

    The article reports on the plan of Johnson & Johnson to invest a total of $1.5 billion in Elan Corp. PLC. In return, the company will transfer its Alzheimer's programs. According to Johnson & Johnson's Srikant Ramaswami, the deal is important as it presented the deal as an opportunity to...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Apr2005, Vol. 4 Issue 4, p2 

    The article offers news briefs in the biotechnology industry. Biogen Inc. and Elan Corp. PLC have decided to withdraw the multiple sclerosis drug Tysabri after two adverse cases occurred in patients treated with it in combination with Avonex. Renovis Inc. has ended a phase two trial of its pain...

  • CNS News Round-Up.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p2 

    Presents news briefs related to the pharmaceutical industry in the United States as of August 2004. Neurochem Inc.'s results for its Alzheimer's disease drug Alzhemed; Food and Drug Administration's review of Elan Corp.'s Antegren application, a drug for the treatment of multiple sclerosis.

  • Elan and Wyeth to take Alzheimer's drug to phase III.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics